Promising developments in the fight against Hep C
source: http://www.google.com/hostednews/afp/article/ALeqM5iG5VqewrzWPaaSzTFZS-20shv0rQ
-
-
- jubal
- added this
WASHINGTON — US scientists have discovered a way to block replication of the hepatitis C virus, potentially leading to better treatment for the top cause of liver cancer in the United States, a study said Wednesday.
In vitro experiments identified a protein that is essential to the reproductive cycle of the hepatitis C virus (HCV), the researchers said.
An altered synthetic version of the protein was found to destroy the virus' ability to replicate, they added.
The altered protein led to compounds that prevented the aggregation or replication of HCV virus, said study lead author Jeffrey Glenn, a professor of gastroenterology and hepatology, and director of Stanford University's Center for Hepatitis and Liver Tissue Engineering.
Because the compounds operate by disrupting a mechanism that is only needed by the virus, the researchers hope any new drugs developed from their research will be less toxic for humans.
Glenn foresees a year to 18 months of preclinical and animal testing before the Food and Drug Administration (FDA) can approve the class of compounds for clinical trials in humans.
The study was published Wednesday in the online edition of Science Translational Medicine.
In vitro experiments identified a protein that is essential to the reproductive cycle of the hepatitis C virus (HCV), the researchers said.
An altered synthetic version of the protein was found to destroy the virus' ability to replicate, they added.
The altered protein led to compounds that prevented the aggregation or replication of HCV virus, said study lead author Jeffrey Glenn, a professor of gastroenterology and hepatology, and director of Stanford University's Center for Hepatitis and Liver Tissue Engineering.
Because the compounds operate by disrupting a mechanism that is only needed by the virus, the researchers hope any new drugs developed from their research will be less toxic for humans.
Glenn foresees a year to 18 months of preclinical and animal testing before the Food and Drug Administration (FDA) can approve the class of compounds for clinical trials in humans.
The study was published Wednesday in the online edition of Science Translational Medicine.
-
- groups:
- Community, News and Politics, Medicine, HIV Alliance
-
-
Susan_Dale
-
-
Here is our latest videos...
The newest PSA for Hepatitis C
http://www.youtube.com/watch?v=7VLjySEI0_kother PSA for Hepatitis C
http://www.youtube.com/watch?v=kqRtNGa7yFwTrailer for new reality show
http://www.youtube.com/watch?v=2fn0qYN5l1QJoin us in the fight to being the simple message "Get Tested for Hepatitis C"
Join our fan page on facepage "Livin' For Racin' Time
--
Susan Dale
Lynn Baxter Studios
Lynnbaxterstudios@gmail.com
918-640-8924Livin' For Racin' Time
www.lynnbaxterstudios.com - 2 years ago
-
Susan_Dale
-
-
jubal
-
Susan_Dale:
Thanks for posting these. They will be much appreciated.
- 2 years ago
-
jubal
-
-
jubal
-
This is a great breakthrough. I wanted you all to know.
- 2 years ago
-
jubal
